What is Tobramycin inhalation solution used for?

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection * †

In a previously published placebo-controlled study, tobramycin inhalation solution (TSI) was shown to improve lung function and other outcomes in patients with cystic fibrosis (CF). The objectives of the present study were to examine the impact of TSIs on the global health-related quality of life (HRQOL) assessment of patients (or their parents) and physicians blind to group assignment, and to determine whether any perceived benefits persisted over time. The global ratings of HRQOL in 520 patients with CF and chronic Pseudomonas aeruginosa infection were retrospectively analyzed. Patients were randomized to receive 24 weeks of treatment with placebo or TSI 300 mg twice daily, both administered in 28 day cycles on the drug (or placebo) followed by 28 days off, for a total of three cycles. After each on-drug cycle, patients or parents and doctors were asked to evaluate whether the patient's condition was better, unchanged, or worse. There was strong agreement between the paired patient / parent and physician global HRQOL ratings across the three cycles. Regression analyzes showed that patients in the TSI group were significantly more likely to report improvements in HRQOL than patients in the placebo group. This effect was found to be both immediate (end of pre-drug cycle 1) and delayed (end of subsequent to-drug cycles 2 and 3) (P.